Finanzen von OptimizeRx Corp (OPRX)OPRXOptimizeRx Corp

Evaluating the bottom line, OptimizeRx Corporation maintains a gross margin of 71.32%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -0.43%, while the net margin is -3.43%. These profitability ratios, combined with a Return on Equity (ROE) of 3.68%, provide a clear picture of how effectively OPRX converts its operational activities into shareholder value.

In the context of the broader market, OPRX competes directly with industry leaders such as TRAK and INSE. With a market capitalization of $164.25M, it holds a leading position in the sector. When comparing efficiency, OPRX's gross margin of 71.32% stands against TRAK's 84.72% and INSE's 56.09%. Such benchmarking helps identify whether OptimizeRx Corporation is trading at a premium or discount relative to its financial performance.

Despite recent revenue declines, OptimizeRx has maintained a strong gross margin, currently at 71.32%, and has shown a positive trend in net income, with $5 million reported in Q4 2025. The company has also effectively managed its debt, reducing it to $19 million as of Q2 2026.